The Univeristy of Melbourne The Royal Melbourne Hopspital

A joint venture between The University of Melbourne and The Royal Melbourne Hospital

17 Jun 2021

Doherty Seminar - Associate Professor Sefi Rosenbluh

Add to my calendar 17/06/2021 2:20 pm Australia/Melbourne Doherty Seminar - Associate Professor Sefi Rosenbluh DD/MM/YYYY

WHEN
17 Jun 2021
12.00 - 1.00

At this Doherty Seminar, Associate Professor Sefi Rosenbluh from Monash University will present on the topic Large scale pooled CRISPR screens for identification of new drug targets and understanding disease genes. 

Zoom URL: https://unimelb.zoom.us/j/82054663809?pwd=WlI0VVpzNy91ZERxRUUzMWZkU01QQT09 
Zoom webinar ID: 820 5466 3809
Zoom password: 651933

ABSTRACT: 

Joseph (Sefi) Rosenbluh is the Victorian mid-career research fellow. He has made major contributions in functional cancer genomics and our understanding of genetic dependencies in cancer. After completing his PhD at the Hebrew University of Jerusalem, Israel he moved to the Broad Institute of Harvard and MIT as a postdoctoral fellow and later as an instructor of medicine. In 2017, Sefi joined the faculty of Monash university and in addition to heading a research lab he directs the Monash functional genomics platform. His recent focus has been on developing CRISPR technologies for loss of function screens and application of these technologies for identifying new targets for cancer treatment and prediction of cancer risk.

BIO:

Joseph (Sefi) Rosenbluh is the Victorian mid-career research fellow. He has made major contributions in functional cancer genomics and our understanding of genetic dependencies in cancer. After completing his PhD at the Hebrew University of Jerusalem, Israel he moved to the Broad Institute of Harvard and MIT as a postdoctoral fellow and later as an instructor of medicine. In 2017, Sefi joined the faculty of Monash university and in addition to heading a research lab he directs the Monash functional genomics platform. His recent focus has been on developing CRISPR technologies for loss of function screens and application of these technologies for identifying new targets for cancer treatment and prediction of cancer risk.